Tuesday, December 16, 2025

Latest

Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that its CEO, Bryan Howcroft, will be stepping down for personal reasons effective immediately. Howcroft was in the role for just six months.

Taking Howcroft’s place within the company is that of David Piddick, whom Medipharm lists as previously serving as a president and CEO of a “Canadian pharmaceutical company.” That pharma company is believed to be Purdue Pharma Canada, whom notably faced numerous lawsuits related to the opioid pandemic which ultimately lead to a bankruptcy filing in the US. Piddick will also serve on the firms board of directors.

Piddick reportedly has over two decades worth of senior leadership experience within the healthcare industry. He currently holds a MBA from Northwestern University.

“In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team’s current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders,” commented Piddick on his appointment.

As part of Piddick’s compensation package, he was issued 14.8 million RSU’s in connection with his appointment, as well as 5.2 million stock options.

Howcroft meanwhile has exited his role from the firm entirely, announcing this morning he will also be vacating his position on the firms board.

Medipharm Labs last traded at $0.145 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Japan Gold Concludes Geophysical Survey At Hakuryu Project For Drill Targeting

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Related News

MediPharm Labs Report sees Quarterly Revenue Drop 25%

This morning MediPharm Labs (TSX: LABS) released their fourth quarter results for the year ended...

Monday, March 30, 2020, 09:40:29 AM

Medipharm Labs Applies for Nasdaq Listing

Medipharm Labs (TSX: LABS) announced this morning that it has submitted an application for listing...

Tuesday, November 5, 2019, 09:37:00 AM

Medipharm Labs CFO Resigns From Company For Family Reasons

Medipharm Labs (TSX: LABS) this morning announced changes to their leadership team within a brief...

Thursday, November 12, 2020, 07:41:36 AM

Medipharm Labs and Cronos Group Sign Second Manufacturing Agreement

Medipharm Labs (TSX: LABS) and Cronos Group (TSX: CRON) (NASDAQ: CRON) have entered into their...

Thursday, September 19, 2019, 09:23:17 AM

Medipharm Labs Increases Bought Deal To $29.0 Million

Medipharm Labs (TSX: LABS) has increased the size of the bought deal financing announced last...

Tuesday, March 2, 2021, 09:26:39 AM